ArticleJournal of breast cancer2025
Oncologic Outcome of Immediate Breast Reconstruction Following Mastectomy in Patients With Ipsilateral Breast Tumor Recurrence.
Article in Journal of breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeThe prevalence of immediate breast reconstruction (IBR) after mastectomy in patients with breast cancer is increasing. However, the applicability of IBR in cases of ipsilateral breast tumor recurrence (IBTR) remains limited. This study evaluated the oncological outcomes of total mastectomy (TM) alone and TM followed by IBR in patients with IBTR.
methodsThis retrospective analysis encompassed patients with IBTR who underwent TM, with or without subsequent IBR, between 2008 and 2018. The exclusion criteria were a third recurrence, delayed reconstruction, chest wall invasion, distant metastasis, supraclavicular or internal mammary lymph node metastasis, or bilateral breast cancer. The cohort was categorized into two groups: TM-only and TM with IBR.
resultsIn total, 123 patients were included in this study (TM-only: n = 48, TM with IBR: n = 75). The median follow-up period were 52 and 51 months, respectively (
conclusionOur results suggest that IBR after TM is a feasible treatment option for patients with IBTR from a prognostic perspective. Nonetheless, the selection of suitable candidates is crucial, considering the observed increase in complications and potential biases inherent in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.